Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

CEO Dave Ricks said Lilly is now considering expanding the vial offering. “We’d like to lower the entry cost and we’d like to have more doses available. That’s not something we’re ...

“I’d call it more forecasting precision than market ... the JPMorgan Healthcare Conference in San Francisco. Typically, Lilly sees “a bit of a build” in inventory levels at the end of ...